Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oliver & Co who wrote (2768)	11/13/1997 9:45:00 PM
From: Joe E.	Read Replies (2) of 6136

Thanks for your note on NIH guidelines. Re: <<I start patients on treatment asap, if they have virus circulating, that means that active replication is taking place. The longer you wait, the lower the CD4, the more damage to the immune system. And we know how hard immune reconstitution is. Once you lost a memory cell, you will most likely never get it back.>> Reading the guidelines it seemed to me that they were somewhat concerned that patients without symptoms or a significantly depressed immune system would not maintain the treatment regimen, thus encouraging resistance. So in a sense IMO they were more concerned with the spread of resistant virus than the optimal health of the patient at hand.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next